Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (Pembrolizumab) Merck and NanoString Technologies, Inc. announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in multiple tumor types. [NanoString Technologies, Inc.] Press Release Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Head and Neck Cancer Amgen and Merck announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen’s investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase I, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck. [Amgen Inc.] Press Release Peregrine Pharmaceuticals Enters into Research Collaboration to Investigate Novel PS-Targeting Immunotherapy Combinations Peregrine Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, announced that the company has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to explore the potential of Peregrine’s proprietary phosphatidylserine (PS)-targeting antibody platform. [Peregrine Pharmaceuticals, Inc.] Press Release bluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy bluebird bio, Inc. and Five Prime Therapeutics, Inc. announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor T cell therapies using Five Prime’s proprietary human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors. [bluebird bio, Inc.] Press Release Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies Juno Therapeutics, Inc. and Editas Medicine announced an exclusive collaboration focused on creating chimeric antigen receptor (CAR T) and high-affinity T cell receptor (TCR) therapies to treat cancer. [Juno Therapeutics, Inc.] Press Release Cancer Genetics Selected to Power Next-Generation Sequencing Services for ReproCELL, a Global Regenerative Medicine Market Leader, in a Multi-Year Agreement Cancer Genetics, Inc. announced that it was selected by ReproCELL, Inc. to provide next-generation sequencing based services and molecular information to enhance ReproCELL’s translational medicine initiatives. [Cancer Genetics, Inc.] Press Release Alnylam Initiates Phase I Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP) Alnylam Pharmaceuticals, Inc. announced that it has initiated a Phase I clinical trial with ALN-AS1, a subcutaneously administered investigational RNAi therapeutic targeting ALAS1 for the treatment of acute hepatic porphyrias, including AIP. [Alnylam Pharmaceuticals, Inc.] Press Release Regeneus Receives Approval for Personalized Cancer Immunotherapy Trial Regeneus has received ethics approval to commence its first-in-human trial for a personalized therapeutic cancer vaccine that is aimed at harnessing the body’s own immune system to fight cancer cells. [Regeneus Ltd.] Press Release MCW Researcher to Study Gene Therapies for Hemophilia A researcher at the Medical College of Wisconsin (MCW) has received a four-year, $1.5 million dollar grant from the National Institutes of Health’s National Heart, Lung, and Blood Institute to continue her study of blood platelet gene therapies for hemophilia A, a genetic bleeding disorder. [Medical College of Wisconsin] Press Release |